Presseinfo / Best-in-class tissue imager introduced at ISSCR Annual Meeting in Hamburg

myriamed and SYNENTEC are proud to unveil the myrImager - a groundbreaking platform for high-content-analysis of pluripotent stem cell-derived heart muscle, skeletal muscle and connective tissue.

The myrImager was developed based on myriamed’s unrivaled expertise in pluripotent stem cell-based tissue formulations and their phenotypic analyses. It images heart muscle, skeletal muscle and connective tissue formulations prepared in myriamed proprietary myrPlates. SYNENTEC as expert in microscopic solutions for high-content-screens took on the challenge to re-engineer the myrImager to develop it into a unique product for the stem cell community.

SYNENTEC describes the cooperation with Myramed as follows: "Our 20 years of experience in the development of automated cell imaging microscopes enables us to optimally capture the specific requirements of our customers in the pharmaceutical and biotech sectors. The cooperation with Myriamed therefore seemed extremely sensible and obvious to us, as our automated cell imaging microscopes already cover the imaging market worldwide and we can now perfectly complement the 3D stem cell area with the myrImager, especially in the macroscopic area for the detection and analysis of myrPlates. We are delighted to have made this new screening platform possible together with the excellent team at Myriamed."

Dr. Tim Meyer from the University Medical Center Göttingen, as co-developer and user, explains that: "the use of myrPlates enables investigators to prepare in a highly robust and reproducible manner engineered heart muscle, skeletal muscle and connective tissue which now can be studied longitudinally with the myrImager in standard cell culture incubators."

As the world's leading event for stem cell research and regenerative medicine, ISSCR 2024 in Hamburg provides the perfect place to meet myriamed and SYNENTEC to learn about our new product lines.

About myriamed GmbH:
myriamed GmbH was founded in 2012 as a spin-off of the University Medical Center Göttingen to provide innovative cell and tissue models for drug discovery applications.

https://www.myriamed.com/ 

About SYNENTEC:
The SYNENTEC GmbH was founded in 2005 to revolutionize high-content cell imaging. SYNENTEC develops automated high-throughput cell culture microscopes, lab-automation peripherals and associated software solutions. In addition to our portfolio product we develop customized solutions for our clients.

https://synentec.com/ 

myrPlate and myrImager publications:

• Meyer T, Tiburcy M, Zimmermann WH (2019) Engineered Heart Tissue-on-Plate Models for Phenotypic Drug Screens. Adv Drug Deliv Rev 140:93-100

• Tiburcy M, Meyer T, Liaw NY, Zimmermann WH (2020) Generation of Engineered Human Myocardium in a Multi-well Format. STAR Protoc. 1:100032.

• Santos GL, DeGrave AN, Rehman A, Al Disi S, Xhaxho K, Schröder H, Bao G, Meyer T, Tiburcy M, Dworatzek E, Zimmermann WH, Lutz S (2022) Using different geometries to modulate the cardiac fibroblast phenotype and the biomechanical properties of engineered connective tissues. Biomater Adv. 139:213041.

• Seibertz F, Rubio T, Springer R, Popp F, Ritter M, Liutkute A, Bartelt L, Stelzer L, Haghighi F, Pietras J, Windel H, Díaz I Pedrosa N, Rapedius M, Döring Y, Solano R, Hindmarsh R, Shi R, Tiburcy M, Brügmann T, Kutschka I, Streckfuss-Bömeke K, Kensah G, Cyganek L, Zimmermann WH, Voigt N (2023) Atrial fibrillation-associated electrical remodelling in human induced pluripotent stem cell-derived atrial cardiomyocytes: a novel pathway for antiarrhythmic therapy development. Cardiovasc Res. 119:2623-2637.

• Kyriakopoulou E, Versteeg D, de Ruiter H, Perini I, Seibertz F, Döring Y, Zentilin L, Tsui H, van Kampen SJ, Tiburcy M, Meyer T, Voigt N, The Netherlands ACM Registry, van Tintelen JP, Zimmermann WH, Giacca M, van Rooij E (2023) Therapeutic efficacy of AAV-mediated restoration of PKP2 in arrhythmogenic cardiomyopathy. Nat Cardiovasc Res 2:1262-1276

• Shahriyari M, Rinn M, Hofemeier AD, Babych A, Zimmermann WH, Tiburcy M (2023) Protocol to develop force-generating human skeletal muscle organoids. STAR Protoc. 5(1):102794.

--
Pressebild - hochauflösendes Motiv: Download

myriamed und SYNENTEC present the myrImager in Hamburg
--

Kontakt:
myriamed GmbH
Rudolf-Wissell-Str. 28a
D-37079 Göttingen

T: +49 551 28878-170
E: info@myriamed.com 
https://www.myriamed.com/ 

Über myriamed GmbH:
Die myriamed GmbH mit Sitz in Göttingen wurde 2012 als Spin-off der Universitätsmedizin Göttingen gegründet, um innovative Zell- und Gewebemodelle für die Wirkstoffforschung zu verwerten. myriamed integriert einzigartige, patentierte Zell- (myrCell) und Gewebemodelle für Herz, Skelett, Gehirn und Bindegewebe (myrTissue) in vielseitige Krankheitsmodellierungsplattformen (myrDisease), um phänotypische Hochdurchsatz- und High-Content-Screens (myrScreen) in leistungsstarken „Patient-in-the-Dish“-Modellen zu ermöglichen. Wir bei myriamed sind überzeugt, dass die nächste Generation von Wirkstoffen mit vorhersagbaren Sicherheits- und Wirksamkeitsprofilen in menschlichen Krankheitsmodellen entdeckt und entwickelt werden wird. Mit seiner erstklassigen Expertise und seinem Angebot an bahnbrechenden Zell- und Gewebetechnologien ist myriamed bestrebt, ein erstklassiger Partner für ambitionierte Arzneimittelentwickler zu sein. https://www.myriamed.com/ 

About myriamed GmbH:
myriamed GmbH, based in Göttingen, was founded in 2012 as a spin-off of the University Medical Center Göttingen to exploit innovative cell and tissue models for drug research. myriamed integrates unique, patented cell (myrCell) and tissue models for heart, skeleton, brain and connective tissue (myrTissue) into versatile disease modeling platforms (myrDisease) to enable high-throughput, high-content phenotypic screens (myrScreen) in powerful patient-in-the-dish models. At myriamed, we are convinced that the next generation of drugs with predictable safety and efficacy profiles will be discovered and developed in human disease models. With its world-class expertise and range of breakthrough cell and tissue technologies, myriamed strives to be a premier partner for ambitious drug developers. https://www.myriamed.com/ 

 zu JETZT [PR]